Probiotic trial in early cognitive impairment examines cognition and tau markers

On this page

Study design

This double-blind, placebo-controlled trial randomized 87 older adults with early cognitive impairment to a multistrain probiotic (n=40) or placebo (n=47) for 24 weeks. Measures included plasma pTau181, GFAP and neurofilament light, along with CDR-SB, CERAD, Stroop and Rey-Osterrieth Complex Figure tests.

Findings

Compared with placebo, the probiotic group had lower plasma pTau181 (p<0.001) and improved CDR-SB scores (p=0.010), mainly in the memory domain. Two visuospatial construction measures improved and constructional recall was preserved. No significant between-group differences appeared in MMSE, verbal memory or executive scores.

Limitations and disclosures

The sample and follow-up are too small and short to establish durable clinical benefit or broad generalizability. Biomarker change does not by itself establish meaningful daily-life benefit, and the cognitive findings were selective. Independent trials are needed to test replication and this specific formulation.

This sourced news summary and translation were prepared with AI assistance. Source links, the news date and research limitations are disclosed; this is not a claim of independent medical expert review. News production method.

Sources

• Multistrain probiotics modulate tau pathology and preserve visuospatial cognition in early cognitive impairment: A double-blind, randomized, placebo-controlled trial — Journal of Alzheimer’s Disease · 28 August 2026

Research news is not medical advice or a recommendation to use a substance. Read findings in the context of the study design, participants and limitations. Editorial standards.

← All news